Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171483 | 0.79 | USP30 (0.42) | ALDH1A1HPGD | |
| SCHEMBL5896658 | 0.68 | CYP1A2 (0.39) | USP2CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL3339309 | 0.67 | CYP1A2 (0.37) | CYP1A2CYP2C19HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL3399318 | 0.66 | CYP1A2 (0.36) | CYP1A2HSD17B10ALDH1A1KMT2AHIF1A | |
| SCHEMBL3621172 | 0.65 | BRD4 (0.38) | USP2CYP3A4CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL17176084 | 0.64 | USP2 (0.51) | USP2CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL31278713 | 0.64 | CYP3A4 (0.33) | USP2CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL29424690 | 0.64 | USP2 (0.70) | USP2CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL16992311 | 0.63 | CYP2C9 (0.52) | USP2CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL3813382 | 0.63 | KDM4E (0.37) | CYP1A2HSD17B10ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | USP2 2178/4885CYP1A2 3150/4885CYP3A4 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.